Cargando…

Distribution of fusion transcripts and its clinical impact in patients with acute myeloid leukemia in Sudan

OBJECTIVE: Acute myeloid leukemia (AML) is a common malignant disorder of hematopoietic progenitor cells that caused by chromosomal translocation and the formation of fusion oncogenes. This study determined the frequencies of fusion genes in Sudanese patients with AML and their clinical impacts. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Muddathir, Abdel Rahim Mahmoud, Hamid, Tarig A. M., Elamin, Elwaleed M., Khabour, Omar F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Qassim Uninversity 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934129/
https://www.ncbi.nlm.nih.gov/pubmed/33708041
_version_ 1783660762989854720
author Muddathir, Abdel Rahim Mahmoud
Hamid, Tarig A. M.
Elamin, Elwaleed M.
Khabour, Omar F.
author_facet Muddathir, Abdel Rahim Mahmoud
Hamid, Tarig A. M.
Elamin, Elwaleed M.
Khabour, Omar F.
author_sort Muddathir, Abdel Rahim Mahmoud
collection PubMed
description OBJECTIVE: Acute myeloid leukemia (AML) is a common malignant disorder of hematopoietic progenitor cells that caused by chromosomal translocation and the formation of fusion oncogenes. This study determined the frequencies of fusion genes in Sudanese patients with AML and their clinical impacts. METHODS: This study was conducted at Alzaeim Alazhari University, Khartoum, Sudan. A total of 97 patients with AML were recruited in the study from different clinics in Khartoum state. Quantitative real-time polymerase chain reaction was used to determine types of fusion genes. RESULTS: The highest frequency of genetic defects was observed for AML1-ETO fusion gene (57.6%) followed by MLL-AF9 (35.1%) and FUS-ERG (7.2%). No significant differences in blast cells, hemoglobin, total white blood cells, and platelets were found between different gene fusion groups (P > 0.05). In addition, no differences in the frequency of splenomegaly, hepatomegaly and lymphadenopathy were observed between different gene fusion groups (P > 0.05). With respect to French-American-British (FAB) classification, the M2 and M3 were significantly higher in patients with AML1-ETO fusion (86%, P < 0.01) whereas M4 and M5 were higher in patients with MLL-AF9 fusion (76.5%, P < 0.01). CONCLUSIONS: The study concluded that AML1-ETO and MLL-AF9 fusion genes were predominant in AML Sudanese patients. None of the examined clinical parameters were different between different fusion genes except for FAB stages.
format Online
Article
Text
id pubmed-7934129
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Qassim Uninversity
record_format MEDLINE/PubMed
spelling pubmed-79341292021-03-10 Distribution of fusion transcripts and its clinical impact in patients with acute myeloid leukemia in Sudan Muddathir, Abdel Rahim Mahmoud Hamid, Tarig A. M. Elamin, Elwaleed M. Khabour, Omar F. Int J Health Sci (Qassim) Original Article OBJECTIVE: Acute myeloid leukemia (AML) is a common malignant disorder of hematopoietic progenitor cells that caused by chromosomal translocation and the formation of fusion oncogenes. This study determined the frequencies of fusion genes in Sudanese patients with AML and their clinical impacts. METHODS: This study was conducted at Alzaeim Alazhari University, Khartoum, Sudan. A total of 97 patients with AML were recruited in the study from different clinics in Khartoum state. Quantitative real-time polymerase chain reaction was used to determine types of fusion genes. RESULTS: The highest frequency of genetic defects was observed for AML1-ETO fusion gene (57.6%) followed by MLL-AF9 (35.1%) and FUS-ERG (7.2%). No significant differences in blast cells, hemoglobin, total white blood cells, and platelets were found between different gene fusion groups (P > 0.05). In addition, no differences in the frequency of splenomegaly, hepatomegaly and lymphadenopathy were observed between different gene fusion groups (P > 0.05). With respect to French-American-British (FAB) classification, the M2 and M3 were significantly higher in patients with AML1-ETO fusion (86%, P < 0.01) whereas M4 and M5 were higher in patients with MLL-AF9 fusion (76.5%, P < 0.01). CONCLUSIONS: The study concluded that AML1-ETO and MLL-AF9 fusion genes were predominant in AML Sudanese patients. None of the examined clinical parameters were different between different fusion genes except for FAB stages. Qassim Uninversity 2021 /pmc/articles/PMC7934129/ /pubmed/33708041 Text en Copyright: © International Journal of Health Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Muddathir, Abdel Rahim Mahmoud
Hamid, Tarig A. M.
Elamin, Elwaleed M.
Khabour, Omar F.
Distribution of fusion transcripts and its clinical impact in patients with acute myeloid leukemia in Sudan
title Distribution of fusion transcripts and its clinical impact in patients with acute myeloid leukemia in Sudan
title_full Distribution of fusion transcripts and its clinical impact in patients with acute myeloid leukemia in Sudan
title_fullStr Distribution of fusion transcripts and its clinical impact in patients with acute myeloid leukemia in Sudan
title_full_unstemmed Distribution of fusion transcripts and its clinical impact in patients with acute myeloid leukemia in Sudan
title_short Distribution of fusion transcripts and its clinical impact in patients with acute myeloid leukemia in Sudan
title_sort distribution of fusion transcripts and its clinical impact in patients with acute myeloid leukemia in sudan
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934129/
https://www.ncbi.nlm.nih.gov/pubmed/33708041
work_keys_str_mv AT muddathirabdelrahimmahmoud distributionoffusiontranscriptsanditsclinicalimpactinpatientswithacutemyeloidleukemiainsudan
AT hamidtarigam distributionoffusiontranscriptsanditsclinicalimpactinpatientswithacutemyeloidleukemiainsudan
AT elaminelwaleedm distributionoffusiontranscriptsanditsclinicalimpactinpatientswithacutemyeloidleukemiainsudan
AT khabouromarf distributionoffusiontranscriptsanditsclinicalimpactinpatientswithacutemyeloidleukemiainsudan